Trial Profile
A Study to Evaluate GlaxoSmithKline (GSK) Biologicals' Investigational Vaccination Regimen in Healthy Young Adults.
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 10 Sep 2023
Price :
$35
*
At a glance
- Drugs GSK 2838497A (Primary) ; Adjuvants; Hepatitis B vaccine recombinant
- Indications Haemophilus infections; Hepatitis B; Pneumococcal infections
- Focus Adverse reactions
- Sponsors GSK
- 04 Jun 2010 Planned end date changed from 1 Apr 2010 to 1 Jul 2010 as reported by ClinicalTrials.gov.
- 04 Jun 2010 Status changed from completed to active, no longer recruiting as reported by ClinicalTrials.gov.
- 01 Jun 2010 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.